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The ets-family transcription factor ETV6 (TEL) has been shown to be the target of a large number of balanced chromosomal translocations in
various hematological malignancies and in some soft tissue tumors. Furthermore, ETV6 is essential for hematopoietic stem cell function. We
identified ETV6 interacting proteins using the yeast two hybrid system. One of these proteins is the HIV Tat interacting protein (TIP60), a histone
acetyltransferase (HAT) containing the highly conserved MYST domain. TIP60 functions as a corepressor of ETV6 in reporter gene assays.
Fluorescently tagged ETV6 and TIP60 colocalize in the nucleus and an increase in nuclear localization of ETV6 was seen when TIP60 was
cotransfected. ETV6 interacts with TIP60 through a 63 amino acids region located in the central domain of ETV6 between the pointed and the ets
domain. The ETV6 interacting region of TIP60 mapped to the C2HC zinc finger of the TIP60 MYST domain. The interaction of TIP60 with full
length ETV6 required an intact acetyltransferase domain of TIP60. Interestingly, the MYST domains of MOZ and MORF were also able to
interact with portions of ETV6. These observations suggest that MYST domain HATs regulate ETV6 transcriptional activity and may therefore
play critical roles in leukemogenesis and possibly in normal hematopoietic development.
© 2007 Elsevier B.V. All rights reserved.Keywords: ETV6; TIP60; MOZ; MORF1. Introduction
Chromosomal rearrangements including balanced transloca-
tions and deletions affecting the short arm of chromosome 12
are frequently observed in several types of hematologic
malignancies including AML, acute lymphoblastic leukemia
(ALL), myelodysplastic syndrome (MDS), chronic myelomo-
nocytic leukemia, and chronic myeloid leukemia [1,2]. About
half of the balanced chromosomal translocations of 12p result in
fusions of ETV6 [3,4]. ETV6 is a member of the ets-family ofAbbreviations: GST, Glutathione-S-transferase; DTT, dithiotreitol; HSV,
Herpes Simplex Virus
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doi:10.1016/j.bbadis.2007.09.006transcription factors and was cloned as the fusion partner of the
platelet-derived growth factor receptor β gene in a t(5;12)(q31;
p13) translocation from the leukemic cells of a patient with
CMMoL [5].
Until now, more than 19 other partner genes of ETV6 have
been identified in hematological malignancies and some solid
tumors (congenital fibrosarcoma, mesoblastic nehproma, secre-
tory breast carcinoma). Six of the fusion partners of ETV6 are
protein tyrosine kinases (PDGFRB, ABL, JAK2, NTRK3,
ARG, SYK, FGFR3, FLT3) [6,7]. The mechanism by which
these fusions lead to the development of leukemia seems to be a
constitutive activation of the tyrosine kinase function through
homodimerization mediated by the pointed domain of ETV6
[6]. Retroviral transduction of murine bone marrow demon-
strated that the ETV6/JAK2 fusion causes malignant hemato-
logic disease in mice. Transgenic mouse models have shown
that the ETV6/PDGFRB fusion causes a myeloproliferative
Table 1
Primer name Sequence
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proteins are able to transform NIH3T3 cells [6].
The mechanisms by which the ETV6/CBFA2 fusion or the
other reported fusion genes of ETV6 (MN1/ETV6, ETV6/EVI-
MDS1, ETV6/BTL, ETV6/ARNT) lead to cellular transforma-
tion are less well understood [6]. There are also some
translocations involving ETV6 that do not give rise to fusion
proteins such as the ETV6/STL and ETV6/ACS2 gene fusions
[8,9] or for which it has been shown that the fusion protein is not
important for leukemogenesis (e.g. the ETV6/CDX2 fusion)
[10,11].
The ETV6/CBFA2 fusion as a consequence of the t(12;21)
(p13;q22) is the most common ETV6 fusion found in up to 30%
of all childhood B-cell ALLs [12,13]. Interestingly, a high
percentage (60–70%) of these leukemias show deletions of the
non-rearranged ETV6 allele [14]. ETV6 has also been mapped
to the smallest region of overlap of deletions affecting the short
arm of chromosome 12 in several hematologic malignancies
[15,16]. These findings hint at a possible tumor suppressor
function of ETV6.
ETV6−/− mice die at day 10.5 to 11.5 of embryonic develop-
ment and exhibit defective yolk sac angiogenesis and massive
apoptosis in mesenchymal and neural tissue [17]. Experiments
using chimeric mice generated with ETV6−/− embryonic stem
cells showed that ETV6 is essential for the establishment of adult
hematopoiesis in the bone marrow [18]. Recently, it has been
shown that disruption of ETV6 causes loss of hematopoietic
stem cells in adult bone marrow [19].
In order to arrive at a better understanding of the physio-
logical function of ETV6, which plays such a pivotal role in
leukemogenesis and normal hematopoietic development, we
used a yeast two hybrid screen to identify proteins that interact
with ETV6. The MYST domain histone acetyltransferase TIP60
was identified in our screen and its interaction with ETV6
characterized in detail.ETV6 1T 5′-gactccgaattca t g t ctgagactcctgctc-3′
ETV6 58T 5′-gtggtggaattc c a a tttactggagcagg-3′
ETV6 118T 5′-gactccgaattcc a g c atattctgaagcagag-3′
ETV6 219T 5′-cgttgaattcc a g g gacccaggccgcac-3′
ETV6 234T 5′-ccatgaattcc c t c tgtcagtgtctccc-3′
ETV6 249T 5′-ccatgaattct c c g agtcccacccgaag-3′
ETV6 282T 5′-ccatgaattcc g g c actccgtggatttc-3′
ETV6 340T 5′-gaacgaattcc t g c tttgggattacgtc-3′
ETV6 59B 5′-cctgtgtctagaaa a t t ggctgcaagcgc-3′
ETV6 126B 5′-gctgactctagacga g g t ttcctctgcttc-3′
ETV6 287B 5′-ctgtctagag a a a tccacggagtgccg-3′
ETV6 317B 5′-gctgtctagag t g g ttcatgtaagccag-3′
ETV6 345B 5′-cctgtgtctag a c g taatcccaaagcag-3′
ETV6 420B 5′-ctgctctagac a t a aacctgaacaaaagcc-3′
TIP60 6T 5′-ctctgaattcg a g a taatcgagggctgccgc-3′
TIP60 148T 5′-ctctgaattca a a c ggaaggtggaggtggtt-3′
TIP60 253T 5′-tctcgaattcg a a c tcaccacattgcctgtc-3′
TIP60 287B 5′-cctatgtcgac t g t cgtaggtcacacttggt-3′
TIP60 357B 5′-cctatgtcgacc t t g gagaagtagcccacga-3′
MOZ 511T 5′-gctgaattcg t c a ttgagtttgggaagta-3′
MOZ 708B 5′-gacgtcgacg t c a ttttggtgataaaggc-3′
MORF 426T 5′-gctgaattcc g g t acccttctgtgattga-3′
MORF 632B 5′-gacgtcgag a t g ctgatgtgcctctcat-3′
Primer name: The number indicates the first (in the case of T=top strand
primers) or the last (in the case of B=bottom strand primers) amino acid. The
codons of the first or last amino acid are underlined in the primer sequence.2. Materials and methods
2.1. Plasmid construction
The bait plasmid for the yeast two hybrid screen was constructed by
inserting the ETV6 cDNA (obtained from Dr. Golub) in frame into the EcoRI
cloning site of the pGBT9 (Clontech). This plasmid (pGBT9/ETV6) expresses
ETV6 as a fusion gene with the yeast GAL4 DNA binding domain (aa 1–147 of
GAL4).
The following portions of ETV6 were cloned in frame with the GAL4
DNA binding domain (aa 1–147) into the eukaryotic expression plasmid
pSG424 [72] and/or into the yeast expression vector pGBT9 (Acc #U07646,
Clontech): 1) aa 1–652 (full length); 2) aa 1–59; 3) 58–126; 4) aa 1–126; 5)
aa 118–345; 6) aa 118–218; 7) aa 219–345; 8) 219–287; 9) 282–345; 10)
249–287; 11) 234–287; 12) 234–317; 13) 219–317; 14) 249–317; 15) 340–420.
Construct 6) (aa 118–218) was derived from construct 5) by cutting the insert at
the SacI site at position 674 of ETV6.
The following portions of TIP60 (β isoform) were cloned in frame with
the GAL4 activation domain into the yeast expression vector pGAD424
(Acc #U07647, Clontech): 1) aa 6–357; 2) aa 148–357 and 3) aa 253–287. The
acetyltransferase activity of TIP60β was disrupted by site-directed mutagenesis
using Quick Change according to the manufacturer's instructions (Stratagene).
The conserved amino acids Gly (aa 380) and Leu (aa 385) in the acetyl co-
enzyme A binding site of TIP60β were changed into aspartic acid and serine,respectively. The resulting TIP60β-DRSmutant has no acetyltransferase activity
(HAT mutant) [20].
The MYST domains of MOZ and MORF were amplified by RT-PCR and
cloned in frame into the multiple cloning site of pGAD424 using EcoRI and
SalI.
The primers used for construction of the different deletion mutants of ETV6
and TIP60 as well as the primers for the amplification and cloning of the MOZ
and MORF MYST domains are listed in Table 1. The integrity of all yeast and
mammalian expression constructs was verified by sequence analysis.
As a reporter in the cotransfection assays, the plasmid GAL45tkLUC was
used. This plasmid was constructed by replacing the chloramphenicol
acetyltransferase gene (CAT) in GAL45tkCAT [21] with the firefly luciferase
gene. This was accomplished by excising the CAT gene from GAL45tkCAT
using BglII and SmaI and replacing it by a BglII–SalI fragment containing the
luciferase gene from pGL3-Basic plasmid (Promega). The resulting construct
expresses the luciferase gene under the control of the Herpes simplex virus
thymidine kinase promoter.
The pTR334 and pTR89 reporter plasmids were obtained from Scott Hiebert
[22]. pTR344 contains the firefly luciferase gene that is under the control of the
stromelysin-1 promoter, which has an ets and an ETV6 binding site; pTR89
does not contain these binding sites and served as a control.
The pECFP-C1-ETV6 plasmid was constructed by removing the coding
sequence of ETV6 from pGBT9-ETV6 with BglII and SalI and inserting it into
pECFP-C1 (Clontech). For pEYFP-N1-TIP60 the complete coding region of
TIP60beta including the first 5 codons was amplified by PCR from pGAD-GH-
TIP60 using linker primers (N-terminus: 5′-CAT CTC GAG AAG ATG GCG GAG GTG
GGGGAGATAATCGAGGGC-3′ and C-terminus: 5′-GTAGAATTCGCCACTTCCCCCTCT
TG-3′) and then inserted into the XhoI and EcoRI sites of pEYFP-N1 (Clontech).
The pCMV-3B-ETV6 plasmid was constructed by inserting the ETV6 cDNA in
frame into the EcoRI cloning site of pCMV-3B (Stratagene). This plasmid allows
the expression of ETV6 with a c-myc-tag in mammalian cells.
2.2. Yeast two hybrid screen
Yeast strain CG-1945 (Clontech) was transformed with the pGBT9/ETV6
bait plasmid using the lithium-acetate procedure. The resulting yeast strain was
transformed with a commercial HeLa cDNA library (Clontech) cloned into
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leucine, tryptophan, and histidine supplemented with 20 mM 3-amino-1,2,4-
triazole (3-AT) were picked for further analysis. The bait plasmid was removed
from clones exhibiting a positive beta-galactosidase reaction by overnight
growth in YPD medium and subsequent screening of clones on appropriate
dropout plates. Only those clones that did not show activation of the HIS3 and
LAC-Z reporter genes in the absence of the bait plasmid were analyzed further.
2.3. GST pulldown
The ETV6 cDNA was subcloned into pBluescript IISK (Stratagene) and
35S-methionine-labelled ETV6 protein was prepared from 1 μg of this plasmid
using T3 RNA polymerase and a reticulocyte lysate coupled transcription
translation kit (Promega) in a 50 μl volume. Prey cDNA inserts were released
from pGAD-GH with EcoRI and XhoI and cloned into EcoRI and SalI
digested pGEX-4T [73]. GST fusion proteins were expressed in E. coli strain
BL21 (Stratagene) and purified from bacterial proteins by incubation with
glutathione sepharose beads. 25 μl of the transcription translation reaction was
incubated with 30 μl of sepharose bound GST fusion proteins or sepharose
bound GST as control in 200 μl protein binding buffer (50 mM K-phosphate
pH 7.5, 100 mM KCl, 10% glycerol, 0.1% Triton X-100). After extensive
washing of the beads with binding buffer the beads were boiled and separated
on an 8% SDS-PAGE gel. The dried gel was exposed to X-ray film at room
temperature overnight.
2.4. Reporter gene assays
1×105 NIH3T3 or HEK293T cells were transiently transfected with a total
of 1.7 to 2 μg plasmid DNA in 35 mm dishes using Superfect transfection
reagent according to the manufacturer's instructions (Stratagene). 0.1 μg of
plasmid pCMV-βGal (Clontech) expressing beta-galactosidase under the
control of the CMV promoter or pRL-Null (Promega, Mannheim), a
promoterless Renilla luciferase plasmid, was included in each transfection as
a control. Cells were harvested after 48 h and lysed in 100 μl lysis buffer
(100 mM KH2PO4 pH 7.8, 0.2% v/v Triton X-100, 0.5 mM DTT). Firefly
luciferase, β galactosidase and Renilla luciferase activity were assayed on a
Berthold LB 592 luminometer (AutoLumat LB953, EG&G Berthold) as
described [23]. In cases were Renilla luciferase was used as a transfection
control, firefly luciferase and Renilla luciferase were assayed using the Dual-
Luciferase reporter Assay Kit (Promega, Mannheim) [24]. Luciferase activity
was normalized to the β galactosidase activity or Renilla luciferase. All assays
were done at least in triplicate. Trichostatin A (TSA) was added to the culture
medium 24 h after transfection at a final concentration of 100 ng/ml.
2.5. Immunoprecipitation
1×106 HEK 293T cells were grown in 100 mm dishes and transfected with
pCMV-3B-ETV6 and pEYFP-N1-TIP60 as described above. In each immuno-
precipitation experiment, 400 μg total cellular lysate was used. Preclearing was
performed by incubating the lysate with 30 μl Protein A-Agarose (Roche,
Penzberg, Germany) and 2 μg normal rabbit IgG (Santa Cruz Biotechnology,
Inc.) in 1 ml binding buffer (10 mM Tris–HCl pH 8, 150 mM NaCl and 0.5%
Triton X-100) for 1.5 h. The resulting supernatant was then incubated for 5 h
with 2 μg of either specific goat anti-c-Myc antibodies (Santa Cruz
Biotechnology, Inc.) or normal goat IgG, which had been previously incubated
with 30 μl Protein A-Agarose for 1.5 h. Incubation steps were carried out at 4 °C
with gentle agitation. Precipitates were washed 3 times with binding buffer,
resuspended in SDS sample buffer and denatured for 5 min at 95 °C.
2.6. Immunoblotting analysis
Immunocomplexes and cellular lysates were electrophoresed on 8% SDS-
PAGE and transferred to nitrocellulose membrane (Hybond™ ECL™,
Amersham Pharmacia biotech). The membranes were blocked for 1 h with
5% nonfat dried milk at room temperature and probed with mix of goat anti-c-
Myc antibodies (Santa Cruz Biotechnology, Inc.) and rabbit anti-GFP
(Molecular Probes Europe BV), followed by secondary antibodies conjugatedto horseradish peroxidase. Proteins were detected with enhanced chemilumi-
nescence (ECL, Amersham Pharmacia biotech).
2.7. Mapping of interacting domains
To map the protein interaction domains of ETV6 and TIP60, yeast strain
CG-1945 was cotransformed with the ETV6 or its deletion mutants cloned into
pGBT9 and TIP60 or its deletion mutants cloned into pGAD-GH/TIP60.
Growth was assayed on dropout plates lacking leucine and tryptophan (-L, -W:
transformation control) or dropout plates supplemented with 20 mM 3-AT
lacking leucine, tryptophan and histidine (-L, -W, -H: interaction assay).
2.8. Subcellular colocalization
For subcellular localization studies (Fig. 2A to E and K), NIH3T3 cells were
grown on coverslips and transfected with pECFP-C1-ETV6 and/or pEYFP-N1-
TIP60 as described above. 48 h after transfection the cells were fixed as
described [25] and examined with a Zeiss Axiovert epifluorescence microscope
equipped with a CCD camera. Images were captured with the Improvision
software (Improvision, Coventry, UK).
For the confocal images (Fig. 2F to I) U2OS cells were grown on coverslips
and cotransfected with pCMV-ETV6 and pEYFP-N1-TIP60 using PEI (Sigma).
After 24 h cells were fixed with PBS 2% paraformaldehyde for 10 min,
permeabilized with PBS 0.1% Triton X for 10 min and blocked with PBS 10%
FCS for 1 h. Coverslips were incubated with polyclonal ETV6 rabbit antibodies
(Santa Cruz) overnight. Following extensive washing with PBS, Cy3-
conjugated secondary antibody (Jackson) was added for 1 h. After further
washing steps DNA was stained with DAPI and mounted using Cytomation
medium (DAKO). Immunostained specimen were analyzed with a confocal
fluorescence laser scanning system (TCS-SP2 scanning system and DM IRB
inverted microscope, Leica, Solms, Germany).3. Results
After screening approximately 1×106 prey plasmids, 22
yeast clones were identified that exhibited growth in the absence
of histidine and were β-galactosidase positive. After removal of
the bait plasmid all 22 clones were negative for β-galactosidase
staining. 11 clones were homologous to the human UBC9 gene
[26]. The sequence of two clones was homologous to the human
HIV1 Tat interactive protein (TIP60) [27]. These two clones
were identical to each other and contained almost the complete
coding region of TIP60 fused in frame to the GAL4 DNA
binding domain from pGAD-GH with the exception of the first
5 amino acids and amino acids 96 to 147. The internal deletion
of 52 amino acids from codon 96 to 147 of TIP60 is due to
alternative splicing, which has been described as the β isoform
of TIP60 [28] (Fig. 1A).
The interaction between TIP60 and ETV6 was verified in
vitro by binding of 35S-methionine-labelled ETV6 to GST-
TIP60 immobilized on glutathione sepharose beads (Fig. 1B).
No binding of ETV6 to the GST-only control is seen.
In vivo interaction was confirmed by coimmunoprecipitation
experiments with c-myc tagged ETV6 and TIP60-YFP after
coexpression in human epithelial kidney cells (Fig. 1C). In myc-
ETV6 expressing cells, TIP6-YFP is coimmunoprecipitated by
anti-c-Myc antibodies. In contrast, normal goat IgG does not
precipitate either one of the proteins.
Aweak positive interaction signal between ETV6 and TIP60
was obtained in the mammalian two hybrid system (2 fold
transcriptional activation compared to the strongest negative
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repressor activity of ETV6 (data not shown).
To delineate the domain of ETV6 which is responsible for
interaction with TIP60, various pGBT9 constructs expressing
ETV6 deletion mutants were cotransformed with the pGAD-
GH/TIP60 plasmid into yeast strain CG-1945. Interaction
between TIP60β and the various portions of ETV6 was assayed
by examining the growth of the double transformants on SD,-Leu, -Trp, -His dropout plates (Fig. 1D). The following ETV6
mutants expressed in pGBT9 showed growth on the selection
plates indicating interaction with TIP60β: ETV6(118–345),
ETV6(218–345), ETV6(282–345), ETV6(234–287), ETV6
(249–287), and ETV6(218–317). The interaction of TIP60
with the ETV6 deletion mutants ETV6(234–287) and ETV6
(218–317) was slightly weaker than with the other deletion
mutants. The fact that ETV6(218–287) does not interact with
1215J. Putnik et al. / Biochimica et Biophysica Acta 1772 (2007) 1211–1224TIP60 might be explained by the presence of ETV6 domains
that block interaction between aa218 and 234 which cannot be
properly controlled by TIP60 in these small deletion mutants.
These results show that 38 amino acids of ETV6 between aa
249–287 and the 63 amino acids between aa 282 and 345 are
each sufficient for interaction with the full length TIP60β
protein.
To further characterize the interaction between TIP60 and
ETV6, transient cotransfection experiments of cyan fluorescent
protein-tagged ETV6 (CFP-ETV6) and yellow fluorescent
protein-tagged TIP60 (TIP60-YFP) were performed in murine
fibroblast. When CFP-ETV6 was transfected alone, it showed
both nuclear and cytoplasmic localization with varying ratios of
nuclear to cytoplasmic CFP-ETV6 in different cells. Some cells
showed both nuclear and cytoplasmic CFP-ETV6 (Fig. 2A),
while others showed only nuclear CFP-ETV6 (Fig. 2B). The
amount of nuclear CFP-ETV6 seemed to stay rather constant.
However, in some cells with both nuclear and cytoplasmic CFP-
ETV6 there was a much greater amount of cytoplasmic CFP-
ETV6 present (Fig. 2B). In single transfections, TIP60-YFP
was almost exclusively found in the nucleus (Fig. 2C). Small
amounts of TIP60-YFP could be seen in the cytoplasm of some
cells when the image was over-exposed (Fig. 2D and E).
Coexpression of myc-ETV6 and YFP-TIP60 revealed coloca-
lization of both proteins in the nucleus. In the confocal scans of
U2OS nuclei, myc-ETV6 and TIP60-YFP showed a very
similar distribution (Fig. 2F, G and H). This was also obvious in
a confocal line scan through one of the nuclei where the
intensity levels for myc-ETV6 (red) and TIP-YFP (green)
showed a similar pattern which was distinct from the curve for
the DAPI stain (blue) (Fig. 2K). Interestingly, in the cotrans-
fection experiments the number of cells exhibiting a cytoplas-
mic CFP-ETV6 distribution decreased and the number of cells
with nuclear CFP-ETV6 increased as the ratio of input TIP60-
YFP to CFP-ETV6 plasmid was increased (Fig. 2L), suggesting
that TIP60-YFP can influence the subcellular localization of
CFP-ETV6.
Several deletion mutants of TIP60 were used to identify the
protein domain of TIP60 that is responsible for interaction with
ETV6. These experiments clearly demonstrated that the 34
amino acids containing the C2HC zinc finger of the TIP60
MYST domain (aa 253–287) are an important interactionFig. 1. (A) Diagrammatic representation of the TIP60α and the TIP60β proteins and
The TIP60β form, which was identified in our yeast two hybrid screen, lacks the first
the acetyl transferase consensus is shown. CD: chromodomain homology. Conserved
an SDS polyacrylamide gel electrophoresis after a GST pulldown experiment using 35
methionine-labelled ETV6 input; lane 2: fraction bound to GST-TIP60 sepharose bead
assay. Western blot analysis of an SDS polyacrylamide gel electrophoresis after a coi
protein coexpressed with YFP-tagged TIP60 in 293T cells. The membrane was probe
Lane 1: Lysate of non-transfected 293 cells immunoprecipitated with c-Myc antibodie
immunoprecipitated with c-Myc antibodies (lane 2) or IgG (lane 3). Lanes 4 and 5: Loa
(lane 4) and 293 cells coexpressing YFP-TIP60p and c-myc-ETV6 (lane 5). (D) Map
with pGAD-GH/TIP60 expressing TIP60 as a fusion with the GAL4 activation domai
with the GAL4DNA binding domain. The upper panel shows the cotransformed clone
the growth of the same cotransformants on plates lacking histidine (-L, -W, -H). Grow
summarized in the lower half of the figure with diagrammatic drawings of the differe
and end of the deletion mutants. The unrelated protein is CALM aa 1–402 fused todomain. Interestingly, this zinc finger is capable of interacting
only with two ETV6 deletion mutants which include aa 282–
345 of ETV6 (ETV6(218–345) and ETV6(282–345)) but not
with the full length ETV6 protein or the deletion mutant
containing aa 118–345. The full length ETV6 protein as well as
the deletion mutant ETV6(118–345) require the complete
TIP60β protein for interaction (Fig. 3A).
Interestingly, the C-terminal deletion mutant of TIP60β
(aa 6–357) that lacked the HAT domain of TIP60 was not
able to interact with the full length ETV6 protein or the
ETV6(118–345) deletion mutant.
To explain this remarkable interaction pattern between the
ETV6 and TIP60β deletion mutants, we hypothesized that
interaction between ETV6 and TIP60β was a two step process:
In the first step a ETV6 might be acetylated by TIP60β which
would result in a conformational change of ETV6; then the zinc
finger of the TIP60β MYST domain would be able to interact
with an exposed interaction interface in the ETV6 central
domain. To test this hypothesis, the TIP60βDRS mutant, which
lacks acetyltransferase activity, was tested for interaction with
ETV6 and several ETV6 deletion mutants in the yeast two
hybrid system. Interestingly, the TIP60β-DRS mutant was not
able to interact with full length ETV6 or with the central domain
(aa 118–345) of ETV6. However, the HAT deficient TIP60β
mutant was still able to interact with the C-terminal half (aa
219–345) and the C-terminal quarter (aa 282–345) of the
central domain of ETV6 (Fig. 3B). This is exactly the same
interaction pattern which was seen with the TIP60β deletion
mutants including the mutant containing only the TIP60β
MYST domain zinc finger. These observations agree with what
would be expected if the HAT activity of TIP60β is needed to
change the conformation of ETV6 to allow efficient interaction.
Since the MYST domain of TIP60 shares more than 60%
identity to the MYST domains of MOZ (myelomonocytic
leukemia zinc finger protein) and to the MYST domain of
MORF (MOZ related factor) (Fig. 1A) we tested the interaction
of ETV6 and various ETV6 deletion mutants with the MYST
domain of these two proteins. As can be seen in Fig. 3C, both
the MOZ and the MORF MYST domain interact with ETV6
deletion mutants ETV6(218–345) and ETV6(282–345). These
are the same ETV6 deletion mutants that interact with the TIP60
MYST domain zinc finger (Fig. 3A). The MYST domains ofmultiple sequence alignment of the MYST domains of TIP60, MOZ and MORF.
5 amino acids. The position of the MYST domain with the C2HC zinc finger and
residues are denoted by an asterisk. (B) GST-Pulldown Assay. Autoradiograph of
S-methionine-labelled ETV6 protein and TIP60 fused to GST. Lane 1: 10% 35S-
s; lane 3: fraction bound to GST-only sepharose beads. (C) Coimmunoprecitation
mmunoprecitation experiment using a c-Myc antibody and c-Myc tagged ETV6
d with specific antibodies against GFP (which also recognizes YFP) and c-Myc.
s. Lanes 2 and 3: Lysate of 293 cells coexpressing YFP-TIP60 and c-myc-ETV6
ding control with 50 μg of protein extracted either from non-transfected 293 cells
ping of the TIP60 interaction domain of ETV6. Yeast clones were cotransformed
n and different deletion mutants of ETV6 cloned into pGBT9 expressed as fusion
s growing on plates supplemented with histidine (-L, -W), the lower panels depict
th in the lower panel indicates interaction. The results of these experiments are
nt ETV6 deletion mutants. The numbers denote the amino acids at the beginning
the GAL4 DNA binding domain [71].
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or the central domain of ETV6 (ETV6(118–345)) just like the
TIP60 MYST domain zinc finger.
It has been shown that ETV6 is a strong transcriptional
repressor containing at least two independent repression
domains. The pointed domain and the central domain (amino
acids 118 to 345). The central domain has been shown to recruit
the corepressors N-CoR and Sin3. Its repressional activity can
be reduced by inhibitors of histone deacetylases like trichostatin
A (TSA) [29]. To investigate whether the TIP60 binding domainplays a role in ETV6 repressional activity we performed
transient transfection experiments. ETV6 and the above
mentioned deletion mutants of ETV6 were expressed as fusion
proteins with the yeast GAL4 DNA binding domain (aa 1–147)
in mouse NIH3T3 fibroblasts. GAL45tkLUC was used as
reporter plasmid.
ETV6 strongly represses transcription of the luciferase
reporter gene in this system. As expected, two domains of
ETV6 can be identified that are responsible for this strong
transcriptional repression (Fig. 4A). One transcriptional
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repression domain localizes to the central region of ETV6 (aa
118–345) [29].
We attempted to further narrow down this second repression
domain with a series of ETV6 deletion mutants. The ETV6
deletion mutants aa 249–287 and aa 249–317 still mediate
transcriptional repression activity which is inhibited by TSA
(Fig. 4A). It should be kept in mind, however, that exact
mapping of this repression domains might be compromised by
incorrect protein folding of the smaller deletion mutants.
The region from aa 282–345 which was shown to interact
with the MYST domains of TIP60, MOZ and MORF shows
almost no repressional activity. Interestingly, upon addition of
TSA this region acts as a transcriptional activator, causing a
threefold increase in luciferase activity (Fig. 4A).
Our initial attempts to demonstrate functional consequences
of TIP60 coexpression in the described reporter gene assays
failed because we were focused on demonstrating relieve of
ETV6 repression by TIP60. However, when Nordentoft and
Jorgensen reported that TIP60 acts as a corepressor for ETV6
[30], we also noticed a slight corepressor activity of TIP60 for
ETV6 (columns 5 and 7 in Fig. 4B). This corepressor activity of
TIP60 became very obvious when only the TIP60 interacting
domain of ETV6 (aa 282–345) was examined. In the absence of
TSA, this region shows slight repressional activity, which is
enhanced slightly by cotransfecting TIP60 (9 and 11 in Fig. 4B).
In the presence of TSA, ETV6(282–345) shows only a very
slight activation of the reporter gene (10 in Fig. 4B). However,
the addition of TIP60 results in two fold repression by this
region (12 in Fig. 4B).
In order to examine the functional consequences of the
ETV6–TIP60 interaction in a more physiological setting, we
used a reporter construct (pTR344) in which the luciferase gene
is under the control of the ETV6-responsive stromelysin-1
promoter. The pTR344 reporter contains an ets and an ETV6
binding site [22]. In transient transfection experiments per-
formed in HEK293T cells, expression of TIP60-YFP led to a
slight reduction (1.3 fold) of reporter gene expression (compare
columns 1 and 2 in Fig. 5). Expression of CFP-ETV6 led to an
approximately 2 fold reduction of reporter gene expression
(compare columns 1 and 3 in Fig. 5) and coexpression of bothFig. 2. Subcellular localization of ETV6 and TIP60. NIH3T3 mouse fibroblasts were
Cell with high expression of CFP-ETV6 (300 ms exposure). CFP-ETV6 can be seen
nuclear expression of CFP-ETV6 (NbC). (B) Cells with moderate expression of CFP-
moderate expression of TIP60-YFP (150 ms exposure). TIP60-YFP is localized in the
and TIP60 (N). (D) Cell with high expression of TIP60-YFP (80 ms exposure). TI
exposure. With this long exposure, a small amount of cytoplasmic TIP60-YFP bec
expression (NNC). Pictures A through E were acquired using a 63× objective. (F
overlapping nuclear distribution pattern. (F) Two neighbouring cells express similar a
in the lower cell and strong in the upper cell. (H) The merged image of the YFP and Cy
patterns in the cell nucleus. myc-ETV6 but not TIP60-YFP spares structures that are p
through the nucleus of the upper cell from panels F through I: The picture shows the tw
levels of the Cy3 channel for myc-ETV6 (red) and the YFP channel for TIP60-YFP (g
TIP60-YFP on the subcellular localization of CFP-ETV6 and vice versa. Three indep
plasmid were performed. The total amount of transfected plasmid DNAwas kept cons
7:1 were used, respectively. For each experiment 100 cotransfected cells were exam
according to N (nuclear), NNC (more nuclear, but also in the cytoplasm), NbC (les
categories for each experiment is shown in the bar graph.CFP-ETV6 and TIP60-YFP resulted in a 5 fold repression of the
reporter gene (column 4 in Fig. 5).
4. Discussion
Analyses of the function of ETV6 as a transcription factor
have shown that it acts as a strong transcriptional repressor in
transient transfection assays [29,31]. The repressional activity
of the central domain (between pointed and ets domain) of
ETV6 is mediated through the recruitment and direct binding of
nuclear corepressors (mSin3a, N-CoR, SMRT) [29,32]. The
pointed domain of ETV6 can also mediate strong transcriptional
repression which is not relieved by the addition of TSA [29] and
is due to the interaction with the polycomb group protein
L3MBTL [33].
It could be shown that ETV6 is able to dimerize via its
pointed domain with the ets-family transcription factor FLI1
[34]. In this context, ETV6 is able to repress the transcriptional
activity of FLI1 [34]. Recently, it could also be demonstrated
that UBC9 can physically interact with ETV6. This interaction
relieves transcriptional repression of ETV6 [35] possibly by
enhancing nuclear export of ETV6 [36]. ETV6–UBC9
interaction leads to the covalent modification of ETV6 by the
small ubiquitin like modifier SUMO-1. Sumoylation of ETV6
seems to be necessary for the cell cycle dependent aggregation
of ETV6 in so-called TEL-bodies [37].
To gain further insight into the function of ETV6 we used the
yeast two hybrid interaction screen to identify protein
interaction partners of ETV6.
One of the interacting proteins was the MYST domain HAT
TIP60 (Kamine et al. [27]). The interaction between ETV6 and
TIP60 seen in the yeast system could be confirmed by in vitro
GST pulldown experiments, by coimmunoprecipitation, through
colocalization studies in mammalian cells and in a mammalian
two hybrid experiment (data not shown). Unfortunately, due to
the low expression levels of the endogenous TIP60 protein in the
cell lines tested, a coimmunoprecipitation of the endogenous
proteins and therefore a formal proof that the two proteins
interact under physicological circumstances, was not possible.
TIP60 was originally isolated in a yeast two hybrid screen
using the HIV Tat transactivator protein as a bait. TIP60 acts astransiently transfected with CFP-ETV6 or YFP-TIP60 expressing plasmids. (A)
in the cytoplasm and the nucleus. Example of cell with more cytoplasmic than
ETV6 (1000 ms exposure). CFP-ETV6 is localized to the nucleus. (C) Cells with
nucleus. (B and C) are examples of cells with only nuclear expression of ETV6
P60-YFP is localized to the nucleus. (E) The same cell as in D but at 700 ms
omes visible. This is an example of a cell with more nuclear than cytoplasmic
to I) Coexpression of myc-ETV6 and TIP60-YFP in U2OS cells reveals an
mounts of immunostained ETV6. (G) The expression of TIP60-YFP is minimal
3 channels shows that myc-ETV6 and TIP60-YFP have overlapping distribution
robably nucleoli. (I) DNAwas counterstained with DAPI. (K) Confocal line scan
o cells with all three channels merged. There is a great similarity in the intensity
reen) which is distinct from the DAPI intensity (blue). (L) Effect of expression of
endent transfections with varying ratios of CFP-ETV6 to TIP60-YFP expressing
tant (2 μg). In experiments 1, 2 and 3 CFP-ETV6 to TIP60-YFP ratios of 3:1, 1:1,
ined and the subcellular localization of CFP-ETV6 and TIP60-YFP was scored
s in the nucleus than in the cytoplasm). The percentage of cells in the different
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Fig. 4. (A) Mapping of ETV6 transcriptional repression domains and effect of TSA on repressional activity. The effect of a series of ETV6 deletion mutants fused to the
GAL4 DBD on a luciferase reporter gene was assayed in transient transfection assays in the NIH3T3 cell line. The luciferase gene was driven by the HSV tk promoter
with moderate basal activity (GAL45tkLUC). All relative light units from the experiments without TSAwere normalized to the value obtained when the GAL4DBD
was expressed alone. The values from the experiments with TSAwere normalized in the same way. The absolute values of the luciferase activity in the experiments
with GAL4DBD alone with TSAwere about 1.5 fold higher than in the same experiments without TSA. The average of three independent experiments is shown. (B)
Influence of TIP60 on the transcriptional activity of ETV6 and the TIP60 interacting domain of ETV6 (aa 282–345). In this assay the same reporter construct
(GAL45tkLUC) as in Fig. 3Awas used. Transient transfection was done in HEK293T cells. ETV6 and ETV6(282–345) were expressed as GAL4DBD fusions. TIP60
was expressed as a YFP fusion protein. All odd experiments (without TSA) were normalized to experiment 1. All even experiments (with TSA) were normalized to
experiment 2. The average and standard deviation of the normalized luciferase activity of three independent experiments are shown.
1219J. Putnik et al. / Biochimica et Biophysica Acta 1772 (2007) 1211–1224a coactivator of HIV Tat [27]. Although there is some debate
whether HIV Tat uses TIP60 as a coactivator or whether the
interaction with HIV Tat and TIP60 serves to prevent TIP60
from activating genes that could interfere with HIV replication
[38]. There are two alternatively spliced forms of TIP60: TheFig. 3. (A) Mapping of the ETV6 interaction domain of TIP60. The upper panel sho
Eight different ETV6 deletion mutants fused to the GAL4 DNA binding domain
activation domain. Each plate assayed all the ETV6 deletion mutants against one of
used are shown diagrammatically in the lower half of the figure. (B) Mapping of the E
eight different cotransformed clones growing on plates lacking histidine (-L, -W, -H)
diagrammatic summary of the results and the point mutations in the acetyltransfera
interaction domain of ETV6. The upper panel shows the growth of 24 yeast cotransfo
in the lower part of the figure.full length α form which is localized exclusively in the nucleus
and the β form which has both nuclear and cytoplasmatic
localization [28]. TIP60β, which lacks 52 amino acids
compared to the α form, was found to interact with ETV6 in
the yeast two hybrid experiments.ws the growth of 24 different yeast cotransformants on plates lacking histidine.
were tested against three different TIP60 deletion mutants fused to the GAL4
the TIP60 deletion mutants. The results of these assays and the deletion mutants
TV6 interaction with the HAT dead TIP60 DRS mutant. The upper panel shows
and on plates supplemented with histidine (-L, -W). The lower panel shows the
se motif of TIP60 DRS. (C) Mapping of the MOZ and MORF MYST domain
rmants on plates lacking histidine. The results are diagrammatically summarized
Fig. 5. Effect of coexpression of ETV6 and TIP60 on stromelysin-1 promoter
driven reporter gene expression. In this assay the pTR334 and the pTR89
reporter constructs were used in which the expression of the firefly luciferase
gene is under the control of portions of the stromelysin-1 promoter [22]. pTR344
contains an ETV6 and an ets binding site, pTR89 lacks these two sites and
served as a control. ETV6 and TIP60 were expressed as CFP and YFP fusion
proteins, respectively, in HEK293T cells. The average and standard deviation of
three independent experiments are shown.
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amino acid sequence of TIP60. This approximately 200 amino
acid long domain derives its name from the four proteins it was
originally identified in: MOZ, YBF2/Sas3, Sas2 and TIP60. It is
an evolutionarily highly conserved, ancient domain [39].
MYST domain proteins can be found in S. cerevisiae (Sas2
and Sas3), C. elegans and D. melanogaster (Mof). The MYST
domain consists of a characteristic C2HC zinc finger and an
acetyl co-enzyme A consensus binding site/acetyl transferase
consensus (Fig. 1A). The N-terminal portion of TIP60 has
homologies to chromodomains (Fig. 1A).
TIP60 has subsequently been shown to interact with a
number of other – mainly nuclear – proteins. Interestingly,
TIP60 can act as a transcriptional coactivator and as a
transcriptional corepressor, depending on its interaction part-
ners. It has been shown to interact with the steroid receptors
(androgen, estrogen and progesterone receptors), the orphan
nuclear receptor RORalpha [40], BCL3, with the intracellular
domain of the human interleukin 9 receptor alpha chain, the
endothelin receptor A, phospholipase A2 and STAT3 [41].
TIP60 forms a trimeric complex with the intracellular tail of the
amyloid precursor protein and the nuclear adaptor protein Fe65
[42] and with STAT3 and HDAC7 [43]. TIP60 enhances
transcriptional activity of steroid hormone receptors in a ligand
dependent manner and is able to in vitro acetylate distinct lysine
residues in the N-terminal tails of histones H2A, H3 and H4 but
not of histone H2B [44,45]. The histone acetyltransferase
activity of TIP60 is controlled by TIP60 Ser90 phosphorylation
via cyclinB/Cdc2 [46]. TIP60 directly acetylates the androgen
receptor (AR) which is important for transcriptional activation
by the AR [47]. TIP60 represses the transcriptional activity of
CREB by direct protein–protein interaction [20] and also
represses the activity of STAT3 [43]. Hlubek et al. found that the
influence (activation or repression) of TIP60 on the HIV Tattransactivator is cell type specific [48]. It was shown recently
that TIP60 is part of a large nuclear multiprotein complex which
is involved in DNA repair and apoptosis [49] and that TIP60 is
upregulated following DNA damage [50]. Interestingly, acety-
lation by TIP60 is required for the exchange of histone variants
at sites of DNA double strand breaks in Drosophila [51]. There
is also evidence that TIP60 and P53 might be coregulated
through MDM2 and that MDM2 dependent downregulation of
TIP60 is one of the mechanisms of MDM2 mediated malignant
transformation [50]. TIP60 also interacts with and stabilizes the
E3 ubiquitin ligase Pirh2. Pirh2 is a P53 responsive gene and is
able to polyubiquitylate P53 [52]. Recruitment of the TIP60
complex was also shown to be important for MYC dependent
gene regulation [53], the activation of NFkappaB target genes
[54] and further the activation of a metastasis suppressor gene
[55].
Recently, Nordentoft and Jorgensen [30] also identified
TIP60 as an ETV6 interaction partner and were able to show
that TIP60 is a corepressor of ETV6. While Nordentoft and
Jorgensen map the TIP60 interaction domain of ETV6 to the ets
domain and the regions flanking the ets domain of ETV6, our
results are slightly different. The ETV6 ets domain in our hands
clearly does not interact with TIP60 (Fig. 1C). However, we
map the TIP60 interaction domain of ETV6 to a region just N-
terminal of the ets domain. Our results allow the interpretation
that the ets domain is not necessary for ETV6–TIP60
interaction. These discrepancies can probably be explained
by the use of different ETV6 deletion mutants in these studies.
We could also demonstrate that there are two apparently
independent TIP60 full length interaction domains in ETV6,
namely from aa 249 to 287 and from aa 282 to 345. These
TIP60 interaction domains do not correlate perfectly with the
second repression domain of ETV6. It seems that parts of both
TIP60 interaction domains are required for maximum
repression (Fig. 4A).
Nordentoft and Jorgensen show that mutations in the MYST
domain zinc finger abolish interaction with ETV6. Our results
show that the CH2C zinc finger on its own is not sufficient for
interaction with full length ETV6 but is still capable of
interaction with the C-terminal portions of the ETV6 central
domain. Putting these results together it can be stated that the
CH2C zinc finger of TIP60 is necessary but not sufficient for
interaction with full length ETV6. These seemingly contradic-
tory observations suggest a complicated mechanism of
interaction between ETV6 and TIP60 which might consist of
two events: A first contact between TIP60 and ETV6 leads to a
conformational change of ETV6; this exposes the central
domain of ETV6 which can then be contacted by the zinc finger
of TIP60. The conformational change of ETV6 might be
brought about by acetylation of ETV6. We could demonstrate
that the TIP60 acetyltransferase function is required for
interaction of TIP60 with full length ETV6. A TIP60
acetyltransferase dead mutant failed to interact with full length
ETV6 but was still able to interact with the same portions of
ETV6 that also showed interaction with the zinc finger of TIP60
(Fig. 3B). These results are compatible with the hypothesis that
acetylation of ETV6 by TIP60 is required for their interaction.
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target of acetylation by TIP60 but that another protein in a
hypothetical ETV6–TIP60 complex is the target of TIP60
acetylation.
Nordentoft and Jorgensen first reported that TIP60 is a
corepressor of ETV6 using both GAL4-DNA binding site
domain ETV6 fusions and a reporter plasmid that uses artificial
ets binding sites. We extend these observations by showing that
TIP60 is also a corepressor in the setting of the naturally ETV6-
responsive stromelysin-1 promoter. The corepressor function of
TIP60 is also evident when only the TIP60 interacting domain
of ETV6 (aa 282–345) is used in the GAL4 reporter system
(Fig. 4B, experiments columns 9–12). This small region of
ETV6 does not mediate transcriptional repression on its own
and in fact is able to stimulate transcription when cellular HATs
are blocked by TSA (Fig. 4A).
Our colocalization studies in mammalian cells show that
TIP60 and ETV6 have a very similar intranuclear distribution
pattern, making interaction between these two proteins very
likely. Interestingly, higher levels of TIP60 expression lead to
more cells that exhibit a predominant nuclear distribution of
ETV6 (Fig. 2). Whether this is an artifact of our system or
whether higher levels of TIP60 expression lead to a redistribu-
tion of ETV6 under certain circumstances (e.g. after UV
damage) needs to be examined.
MYST domain HATs have been shown to be involved in a
variety of transcription regulatory processes both in gene
activation and in gene silencing. The D. melanogaster MYST
domain protein Mof is required for dosage compensation in the
male fly, which is accomplished by increasing the transcrip-
tional activity of the single male X chromosome [39]. The SAS2
and SAS3 proteins in yeast on the other hand are involved in the
silencing of genes near the telomeres and the mating type lociFig. 6. Diagrammatic representation of leukemic fusion gene network. Genes invol
denote fusion genes. MYST domain HATs are in dark gray boxes, other HATs in lig
other. Note that not all fusions of ETV6 and MLL are shown.[56]. The yeast MYST domain family member ESA1 is
essential for growth [57].
HATs are commonly viewed as coactivators of transcription
factors, which exert their transcriptional activation function
through the acetylation of core histones thereby facilitating gene
transcription by loosening nucleosomal packaging. However,
there is mounting evidence that histones are not the only targets
of acetylation by these enzymes (see acetylation of AR by
TIP60) and that not all acetylation of histones inevitably leads to
increased transcriptional activity [58,59].
A very interesting aspect of the ETV6–TIP60 interaction is
the fact that the human MYST domain HAT MOZ (myelomo-
nocytic zinc finger protein) had originally been identified in a
leukemic fusion protein as the partner of CBP in a t(8;16)
translocation [60]. Two other fusion partner genes of MOZ have
been identified: TIF2 and P300 [61–63]. Recently, a fusion of
the MOZ related factor MORF with CBP fusion has been
described as the result of a t(10;16)(q22;p13) in cases of acute
myeloid leukemia [64].
The fact that the C-terminal fourth of the central domain (aa
282–345) of ETV6 interacts specifically with the zinc finger of
the TIP60 MYST domain prompted us to ask whether the
MYST domains of MOZ [60] and the related MORF [65]
protein would also be able to interact with this region of ETV6.
This was indeed the case. Interestingly, the same interaction
pattern that was seen between the various ETV6 deletion
mutants and the TIP60 MYST domain could also be observed
with the MOZ and MORF MYST domains. In light of the
results of Nordentoft and Jorgensen, who showed that the C-
terminal 34 amino acids of TIP60 are critical for interaction, we
would expect that an additional domain (possibly C-terminal to
the MYST domain) of MOZ and MORF is required for
interaction with full length ETV6. Detailed functional studies ofved in leukemic translocations are shown in boxes. Boxes connected by a line
ht gray boxes. Important protein interactions are shown by boxes touching each
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activation domain and a transcriptional repression domain.
These functions are not dependent on the HAT activity of
MORF [65]. It is interesting to note that the C2HC MYST
domain zinc finger of MOZ is essential for the transforming
properties of the MOZ/TIF2 fusion protein [66]. Deguchi et al.
speculate that this might be due to the loss of a putative zinc
finger-mediated nucleosomal binding of the MOZ/TIF2 fusion
protein. In light of our results, this loss of transforming activity
could also be due to the inability of MOZ/TIF2 to interact with
ETV6 (or another protein).
The discovery of the interaction between ETV6 and MYST
domain HATs links the two large fusion gene networks centered
on ETV6 and MLL [67] (Fig. 6). There is thus growing
evidence that the alterations of proteins involved in chromatin
control like HATs, and especially MYST domain HATs, play an
important role in leukemogenesis. In this context, it is quite
interesting that Nordentoft and Jorgensen report interaction of
ETV6 with ZNF198, a fusion partner of FGFR1 [68,69].
FGFR1 itself has been reported to be fused to BCR in a
myeloproliferative disorder [70].
It will require further studies to explore the mechanism of the
ETV6–TIP60 interaction and its physiological relevance.
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